Eli Lilly and Co. (LLY) Surged on Persistent Investor Enthusiasm

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q1 2025 investor letter. A copy of the letter can be downloaded here. The market faced a challenging start to 2025, with the S&P 500 Index declining 4.27% and the Russell 1000 Growth Index falling 9.97% in the first quarter. Against this backdrop, the fund dropped 7.21%, outperforming its growth benchmark. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its first-quarter 2025 investor letter, RiverPark Large Growth Fund highlighted stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company, headquartered in Indianapolis, Indiana. The one-month return of Eli Lilly and Company (NYSE:LLY) was -10.20%, and its shares lost 11.26% of their value over the last 52 weeks. On May 30, 2025, Eli Lilly and Company (NYSE:LLY) closed at $737.67 per share, with a market capitalization of $662.233 billion.

RiverPark Large Growth Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q1 2025 investor letter:

“Eli Lilly and Company (NYSE:LLY) was a top contributor in the first quarter as investor enthusiasm remained strong around the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro. Despite ongoing capacity constraints and elevated expectations, Lilly continued to demonstrate robust demand trends and progress in expanding manufacturing to meet future needs. With a pipeline that also includes promising therapies in Alzheimer’s, oncology, and immunology, we believe Lilly is well positioned for long-term revenue and earnings growth. Its combination of market leading products, innovative pipeline, and growing free cash flow generation makes it one of the most compelling large-cap pharma investments today.”

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

Eli Lilly and Company (NYSE:LLY) is in 21st position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the first quarter, which was 115 in the previous quarter. Eli Lilly and Company (NYSE:LLY) reported strong results in first quarter of 2025, with revenue increasing 45% compared to Q1 2024. While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.

In another article, we covered Eli Lilly and Company (NYSE:LLY) and shared the list of major stocks to buy according to billionaires. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.